X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs STERLING BIOTECH - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD STERLING BIOTECH ORCHID PHARMA LTD/
STERLING BIOTECH
 
P/E (TTM) x -0.6 -1.9 - View Chart
P/BV x 0.4 0.1 563.2% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ORCHID PHARMA LTD   STERLING BIOTECH
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
STERLING BIOTECH
Dec-13
ORCHID PHARMA LTD/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs19411 1,847.6%   
Low Rs353 1,029.4%   
Sales per share (Unadj.) Rs276.526.8 1,031.3%  
Earnings per share (Unadj.) Rs-79.2-15.0 529.6%  
Cash flow per share (Unadj.) Rs-43.5-5.5 795.4%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs53.954.9 98.3%  
Shares outstanding (eoy) m70.45267.87 26.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.40.3 159.7%   
Avg P/E ratio x-1.4-0.5 311.1%  
P/CF ratio (eoy) x-2.6-1.3 207.1%  
Price / Book Value ratio x2.10.1 1,676.3%  
Dividend payout %00-   
Avg Mkt Cap Rs m8,0671,862 433.3%   
No. of employees `0002.81.4 206.8%   
Total wages/salary Rs m2,527547 462.1%   
Avg. sales/employee Rs Th6,956.15,303.3 131.2%   
Avg. wages/employee Rs Th902.5403.8 223.5%   
Avg. net profit/employee Rs Th-1,993.0-2,959.0 67.4%   
INCOME DATA
Net Sales Rs m19,4777,181 271.2%  
Other income Rs m40743 955.9%   
Total revenues Rs m19,8847,223 275.3%   
Gross profit Rs m1,103947 116.4%  
Depreciation Rs m2,5192,543 99.1%   
Interest Rs m5,2274,377 119.4%   
Profit before tax Rs m-6,236-5,931 105.1%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-125-1,924 6.5%   
Profit after tax Rs m-5,580-4,007 139.3%  
Gross profit margin %5.713.2 42.9%  
Effective tax rate %2.032.4 6.2%   
Net profit margin %-28.7-55.8 51.3%  
BALANCE SHEET DATA
Current assets Rs m11,01414,335 76.8%   
Current liabilities Rs m32,06049,809 64.4%   
Net working cap to sales %-108.1-494.0 21.9%  
Current ratio x0.30.3 119.4%  
Inventory Days Days95403 23.5%  
Debtors Days Days34171 19.7%  
Net fixed assets Rs m29,44055,432 53.1%   
Share capital Rs m705268 263.0%   
"Free" reserves Rs m2,04313,935 14.7%   
Net worth Rs m3,80014,701 25.8%   
Long term debt Rs m9,0189,478 95.1%   
Total assets Rs m46,51073,988 62.9%  
Interest coverage x-0.2-0.4 54.4%   
Debt to equity ratio x2.40.6 368.1%  
Sales to assets ratio x0.40.1 431.5%   
Return on assets %-0.80.5 -151.7%  
Return on equity %-146.9-27.3 538.9%  
Return on capital %-3.7-6.4 58.1%  
Exports to sales %37.925.9 146.2%   
Imports to sales %22.60.2 13,314.9%   
Exports (fob) Rs m7,3781,860 396.7%   
Imports (cif) Rs m4,40612 36,115.6%   
Fx inflow Rs m7,5131,860 404.0%   
Fx outflow Rs m5,64925 22,695.1%   
Net fx Rs m1,8651,835 101.6%   
CASH FLOW
From Operations Rs m1,6821,719 97.8%  
From Investments Rs m-9,860-3,148 313.2%  
From Financial Activity Rs m6,6441,426 465.9%  
Net Cashflow Rs m-1,535-3 45,147.1%  

Share Holding

Indian Promoters % 32.3 33.9 95.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 0.0 -  
FIIs % 3.3 9.9 33.3%  
ADR/GDR % 4.6 16.9 27.2%  
Free float % 55.3 39.3 140.7%  
Shareholders   84,811 21,482 394.8%  
Pledged promoter(s) holding % 54.9 55.9 98.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   AUROBINDO PHARMA  DR. REDDYS LAB  GSK PHARMA  J.B.CHEMICALS  MERCK LTD  

Compare ORCHID PHARMA LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Volatile Note; Airtel, Idea Down by 5%(01:30 pm)

After opening the day in green share markets in India witnessed choppy trading activity and are presently trading above the dotted line.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jan 24, 2018 01:55 PM

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS